# Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

> **NCT06904196** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 78 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **COMBINATION_PRODUCT:** Lenvatinib plus SIRT
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT06904196
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2028-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06904196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06904196, "Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06904196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*